Bemcentinib (R428)

Catalog No.S2841 Batch:S284115

Print

Technical Data

Formula

C30H34N8
Molecular Weight 506.64 CAS No. 1037624-75-1
Solubility (25°C)* In vitro DMSO 30 mg/mL (59.21 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
10% DMSO 40%PEG300 5%Tween80 45%ddH2O
2.5mg/ml Taking the 1 mL working solution as an example, add 100 μL of 25 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO Corn oil
1.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Targets
Axl [1]
(Cell-free assay)
14 nM
In vitro R428 blocks the catalytic and procancerous activities of Axl. R428 inhibits Axl with low nanomolar activity and blocks Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. [1] In a recent study, the Axl inhibitor R428 shows a mean IC50 dose of ∼ 2.0μM for the primary CLL B cells after 24 hours of treatment and normal B-, T-, and natural killer (NK) cells show no significant amount of cell death at this dose of R428 (2.5 μM) under similar experimental conditions. [2]
In vivo Pharmacologic investigations reveal favorable exposure after oral administration such that R428-treated tumors display a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, R428 inhibits angiogenesis in corneal micropocket and tumor models. R428 administration reduces metastatic burden and extends survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis. [1]

Protocol (from reference)

Animal Study:

[1]
  • Animal Models

    MDA-MB-231-luc-D3H2LN Intracardiac Model

  • Dosages

    125 mg/kg

  • Administration

    Oral, twice daily

Customer Product Validation

Data from [Data independently produced by Cancer Res, 2014, 74(18), 5152-64]

Data from [Data independently produced by Biochem Bioph Res Co, 2014, 10.1016/j.bbrc.2014.10.126]

, , FASEB J, 2017, 31(4):1382-1397

Data from [Data independently produced by , , Blood, 2018, doi:10.1182/blood-2018-05-853291]

Selleck's Bemcentinib (R428) has been cited by 132 publications

CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer [ Nat Commun, 2024, 15(1):2818] PubMed: 38561369
Directed differentiation of pancreatic δ cells from human pluripotent stem cells [ Nat Commun, 2024, 15(1):6344] PubMed: 39068220
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia [ Theranostics, 2024, 14(7):2656-2674] PubMed: 38773967
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia [ Theranostics, 2024, 14(7):2656-2674] PubMed: 38773967
Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19 [ J Nanobiotechnology, 2024, 22(1):169] PubMed: 38609998
Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC [ Biochim Biophys Acta Mol Basis Dis, 2024, 1870(6):167249] PubMed: 38768929
Atypical KCNQ1/Kv7 channel function in a neonatal diabetes patient: Hypersecretion preceded the failure of pancreatic β-cells [ iScience, 2024, 27(7):110291] PubMed: 39055936
Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells [ J Biol Chem, 2024, 300(6):107375] PubMed: 38762181
Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro [ Cell Cycle, 2024, 1-13.] PubMed: 38263737
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC [ J Thorac Oncol, 2023, 10.1016/j.jtho.2023.10.017] PubMed: 37924972

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.